ABSTRACT
How do active clinicians get authoritative information on new therapies? Conventional wisdom suggests they consult with local specialists, read the latest editions of medical textbooks and review articles from current professional journals. Occasionally, information on drugs is delivered by representatives of pharmaceutical houses. These avenues work well when dealing with conventional drugs, but how well do they work when a clinician is trying to educate himself about a novel therapy that is not yet accepted by the established medical community?
